OncoMed Pharma Q2 Net Loss Widens - Quick Facts

(RTTNews) - OncoMed Pharmaceuticals, Inc. (OMED) Thursday reported second-quarter 2014 net loss of $15.6 million or $0.53 per share, versus a $9.6 million or $8.83 per share of loss, in the same period last year. On average, 5 analysts polled by Thomson Reuters expected the company to report a loss of $0.03 per share for the quarter. Analysts' estimates typically exclude special items.

Driven by an increase in recognized revenue of the upfront payments received in 2013 under the OncoMed-Celgene collaboration deal, quarterly revenues were $6.0 million, higher than $2.9 million in the second quarter of 2013. Five analysts estimated revenues of $21.28 million for the quarter.